Full text
Earnings transcript
Read the complete earnings call transcript.
KALV
KalVista Pharmaceuticals, Inc.
$19.9
0.13
(0.66%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 1.019B |
| Shares Outstanding: | 724800 |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Benjamin L. Palleiko | |||||
| Full Time Employees: | 150 | |||||
| Address: |
| |||||
| Website: | https://www.kalvista.com |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | -86,167 | 0 |
| EBITDA | -94,368 | -134,280 | -173,326 |
| Operating Income | -110,871 | -140,445 | -187,995 |
| Net Income | -92,907 | -126,644 | -183,444 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 183,202 | 235,404 | 250,770 |
| Total Liabilities | 22,177 | 28,822 | 155,379 |
| Total Stockholders Equity | 161,025 | 206,582 | 95,391 |
| Total Debt | 8,232 | 7,317 | 6,307 |
| Cash and Cash Equivalents | 56,238 | 31,789 | 98,644 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -75,261 | -89,231 | -152,907 |
| Capital Expenditure | -1,196 | -443 | -434 |
| Free Cash Flow | -76,457 | -89,674 | -152,907 |
| Net Income | -92,907 | -126,644 | -183,444 |
| Net Change in Cash | 25,506 | -24,449 | 100,483 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 575,980.497 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 602,942.302 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 589,461.400 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 173,724.996 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 184,371.566 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 179,048.281 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 3.610 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 3.710 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 3.500 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 4 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Pipeline in Biotechnology Sector: KALV, operating in the biotechnology industry within the healthcare sector, focuses on developing novel therapies, as highlighted in the company description. This positions the company favorably for potential breakthroughs, supported by insights from earnings call transcripts emphasizing progress in clinical trials or R&D efforts.
- Solid Liquidity Position: Analysis of balance sheet data indicates a healthy level of cash and cash equivalents relative to total current liabilities, with a strong current ratio (TTM) from key metrics. This provides financial flexibility for ongoing operations and R&D investments.
- Positive Revenue Trends: Income statement data shows consistent revenue growth over recent periods, potentially driven by specific product categories or geographic segments as detailed in revenue product and geo segments. This reflects market acceptance and operational success compared to industry trends.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about KALV valuation
Is KalVista Pharmaceuticals, Inc. (KALV) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for KalVista Pharmaceuticals, Inc. (KALV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is KALV a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KALV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is KALV’s P/E ratio?
You can see KALV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for KALV?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is KALV a good long-term investment?
Whether KALV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
KALV
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
0.66
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 9.24 | Year High: | 21.31 | |
| Price Avg 50: | 16.39 | Price Avg 200: | 14.3 | |
| Volume: | 897328 | Average Volume: | 976673 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeKALV full analysis
Welcome to MARKETSNAP’s SWOT analysis for KalVista Pharmaceuticals! If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into KalVista, a lesser-known player in the biotech space, to uncover what makes this company tick and whether it’s worth a spot in your portfolio. Let’s break it down with a quick overview, some recent developments, and then get into the meat of our SWOT analysis to see where this…
